Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Regorafenib in Relapsed Glioblastoma (REGOMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02926222
Recruitment Status : Active, not recruiting
First Posted : October 6, 2016
Last Update Posted : April 1, 2022
BAYER S.p.A. - Italia
Information provided by (Responsible Party):
Istituto Oncologico Veneto IRCCS

Brief Summary:
This study aims to evaluate the role of Regorafenib in prolonging the overall survival of glioblastoma multiforme patients who progressed after surgery and Stupp regimen with or without bevacizumab.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme Drug: Regorafenib Drug: Lomustine Phase 2

Detailed Description:
The primary aim of the study is to evaluate the overall survival (OS) in the intention to treat (ITT) population. Secondary aims are to evaluate the progression free survival (PFS), safety, objective response rate (ORR), disease control rate (DCR) in the ITT population, and the evaluation of quality of life (QoL). Additional exploratory objectives include the analysis of antiangiogenic and metabolic biomarkers in tissue at first and second surgery (if performed) by the evaluation of certain metabolic features of tumors that could be involved in tumor responses to antiangiogenic drugs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 119 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial
Actual Study Start Date : November 2015
Actual Primary Completion Date : July 2017
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ARM A - Regorafenib
Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.
Drug: Regorafenib
Regorafenib is formulated as tablets of 40mg for oral administration.
Other Name: Stivarga

Active Comparator: ARM B - Lomustine
Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.
Drug: Lomustine
Lomustine is formulated as tablets of 40mg for oral administration.
Other Name: Ceenu

Primary Outcome Measures :
  1. Overall survival [ Time Frame: From the date of randomization to 18 months or to the date of death from any cause ]

Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: From the date of randomization to 18 months or to the date of disease progression or to the date of death, whichever occurs first ]
  2. Objective response rate [ Time Frame: Approximately 36 months ]
    As percentage of patients achieving a complete response plus partial response

  3. Disease control rate [ Time Frame: Approximately 36 months ]
    As percentage of patients achieving a complete response plus partial response plus stable disease

  4. Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events) [ Time Frame: Approximately every 4 weeks through the treatment period up to 30 days after the end of treatment ]
    Graded according to the NCI-Common Terminology Criteria for Adverse Events (CTCAE) v.4

Other Outcome Measures:
  1. Quality of life EORTC [ Time Frame: From the date of randomization, approximately every 3 months until the date of first documented progression or date of death from any cause, or study withdrawal, whichever came first, assessed up to 30 months. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female ≥ 18 years of age
  • Histologically confirmed de novo glioblastoma multiforme (grade IV)
  • First recurrence after adjuvant treatment (surgery followed by radiotherapy and temozolomide chemotherapy with or without bevacizumab) in patients who have not received further therapeutic interventions
  • For patients not undergoing a second surgery at the time of relapse, recurrent disease must include at least one bi-dimensionally measurable contrast-enhancing lesion with clearly defined margins by MRI scan, with minimal diameters of 10 mm, visible on 2 or more axial slices 5 mm apart, based on an MRI scan done within 2 weeks prior to randomization
  • Documented progression of disease as defined by RANO criteria at least 12 weeks after completion of radiotherapy, unless the recurrence is outside the radiation field or has been histologically documented
  • Have adequate bone marrow function, liver function, and renal function, as measured by the following laboratory assessments conducted within 7 days prior to the initiation of study treatment:

    • Hemoglobin >9.0 g/dl
    • Absolute neutrophil count (ANC) >1500/mm3 without transfusions or granulocyte colony stimulating factor and other hematopoietic growth factors
    • Platelet count ≥100,000/μl
    • White blood cell count (WBC) >3.0 x 109/L
    • Total bilirubin <1.5 times the upper limit of normal
    • ALT and AST <3 x upper limit of normal (<5 x upper limit of normal for patients with liver involvement of their cancer and/or have bone metastasis)
    • Serum creatinine <1.5 x upper limit of normal
    • Alkaline phosphatase <2.5 x ULN (<5 x upper limit of normal for patients with liver involvement of their cancer and/or have bone metastasis)
    • PT-INR/PTT <1.5 x upper limit of normal (Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists per medical history)
    • Lipase ≤ 1.5 x the ULN
  • Glomerular filtration rate ≥ 30 mL/min/1.73 m2 according to the Modified Diet in Renal Disease abbreviated formula
  • Analyses of MGMT methylation status on tumoral tissue at first surgery (at own institution)
  • Understand, be willing to give consent, and sign the written informed consent form (ICF) prior to undergoing any study-specific procedure
  • If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment
  • If female and of childbearing potential, or if male, agree to use adequate contraception (eg, intrauterine device, oral contraceptive, or double-barrier method) based on the judgment of the investigator or a designated associate from the date on which the ICF is signed until 8 weeks after the last dose of study drug
  • World Health Organization (WHO) Performance status ≤ 1 (or Karnofsky performance status (KPS) ≥70)) within 14 days prior to the initiation of study treatment
  • Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan.
  • Patients may have undergone surgery for the recurrence; the histological report must document a glioblastoma recurrence. If operated:

    • at least 28 days and maximum 42 days interval from the surgery is required prior to administration of study drugs and patients should have fully recovered
    • Exclusion Criteria:
  • Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)
  • Radiotherapy within 12 weeks prior to the diagnosis of progression, if the lesion is in the radiation field,
  • Have had systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and/or hormonal therapy within 4 weeks prior to initiation of study treatment
  • Positioning of carmustin wafers during first or second surgery
  • Other active or inactive malignancy (except for carcinoma in situ of the cervix, of the prostate or basal cell carcinoma). Malignancy will be considered inactive if patients are in complete remission for at least 3 years prior to study entry
  • Have had prior treatment with regorafenib or any other VEGFR-targeting kinase inhibitor
  • Have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment
  • Are pregnant
  • Are breastfeeding
  • Are unable to swallow oral tablets (crushing of study treatment tablets is not allowed)
  • Have congestive heart failure classified as New York Heart Association Class 2 or higher
  • Have had unstable angina (angina symptoms at rest) or new-onset angina ≤ 3 months prior to screening.
  • Have had a myocardial infarction < 6 months prior to initiation of study treatment
  • Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin
  • Have uncontrolled hypertension (systolic blood pressure [SBP] > 140 mmHg or diastolic blood pressure [DBP] > 90 mmHg) despite optimal medical management
  • Have had arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within 6 months prior to the initiation of study treatment
  • Have an ongoing infection with severity of Grade 2 or above (NCI-CTCAE v 4.0)
  • Have a known history of human immunodeficiency virus infection
  • Have either active or chronic hepatitis B or C requiring treatment with antiviral therapy
  • Have a history of organ allograft
  • Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity
  • Have had a hemorrhage or a bleeding event ≥ Grade 3 (NCI-CTCAE v 4.0) within 4 weeks prior to the initiation of study treatment
  • Have a non-healing wound, ulcer, or bone fracture
  • Have renal failure requiring hemodialysis or peritoneal dialysis
  • Have dehydration ≥ Grade 1 (NCI-CTCAE v 4.0)
  • Have interstitial lung disease with ongoing signs and symptoms at the time informed consent is obtained
  • Have persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (Grade 3, NCI-CTCAE v 4.0)
  • Have any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
  • Have a known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
  • Have any malabsorption condition
  • Recurrent disease located outside of the brain

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02926222

Layout table for location information
IRCCS "Saverio de Bellis
Castellana Grotte, BA, Italy, 70013
Ospedale di Bellaria
Bologna, BO, Italy
Azienda Ospedaliera "G.Rummo"
Benevento, BR, Italy
istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori
Cesena, FC, Italy, 47014
Istituto Neurologico C. Besta IRCCS
Milano, MI, Italy, 20133
Istituto Oncologico Veneto IRCCS, Oncologia Medica 1
Padova, PD, Italy, 35128
Ospedale Santa Chiara
Pisa, PI, Italy, 56126
Azienda Ospedaliero Universitaria S. Maria della Misericordia
Udine, UD, Italy, 33100
Istituto Nazionale Tumori Regina Elena
Roma, Italy, 00144
Azienda Ospedaliera Universitaria Città della Salute e della Scienza
Torino, Italy, 10126
Sponsors and Collaborators
Istituto Oncologico Veneto IRCCS
BAYER S.p.A. - Italia
Layout table for investigator information
Principal Investigator: Vittorina Zagonel, MD Istituto Oncologico Veneto IRCCS
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Istituto Oncologico Veneto IRCCS Identifier: NCT02926222    
Other Study ID Numbers: IOV-GB-1-2014 REGOMA
2014-003722-41 ( EudraCT Number )
First Posted: October 6, 2016    Key Record Dates
Last Update Posted: April 1, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents